A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Official title

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial

Overview

The aim of this study is to evaluates the efficacy of weekly nab-paclitaxel monotherapy compared to the standard regimen of docetaxel plus carboplatin, both supplemented with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Detailed description

In order to compare the effects of nab-PHP and TCbHP chemotherapy regimens in the neoadjuvant treatment of HER2-positive breast cancer, this study randomly divided patients who met the inclusion criteria into 2 groups through a randomized control regimen： the neoadjuvant chemotherapy with 6\*nab-PHP regimen group (experimental group): nab-paclitaxel 125mg/m2 on days 1, 8, and 15 every 21 days as one cycle; 6\*TCbHP regimen (control group): docetaxel 75 mg/m2 + carboplatin (AUC=6) on day 1. Both groups will receive trastuzumab (loading dose 8 mg/kg followed by a maintenance dose of 6 mg/kg) on day 1 and pertuzumab (loading dose 840 mg followed by a maintenance dose of 420 mg) on day 1, every 21 days as one cycle.

Surgery will be performed after completion of neoadjuvant chemotherapy, with intraoperative excision of specimens (breast + axilla) for pathological evaluation.

Comparative analysis of pCR, EFS, iDFS and safety outcomes between the two groups will be conducted using appropriate statistical methods.

Safety evaluation will include the incidence of adverse events, incidence of serious adverse events, dose adjustment rate, and discontinuation rate.

Interventions

• Drug Nab-paclitaxel+ trastuzumab+ patuzumab
  Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
• Drug Docetaxel+ carboplatin+ trastuzumab + patuzumab
  Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Primary outcome measures

• Pathological Complete Response (pCR) [Time frame: through study completion, an average of 1 year]

Secondary outcome measures (5)

• Event-Free Survival (EFS) [Time frame: 5 years after surgery]
• Invasive Disease-Free Survival (iDFS) [Time frame: 5 years after surgery]
• Safety-Number of adverse events and serious adverse events. [Time frame: After each cycle of chemotherapy (21 days as 1 cycle)]
• Tolerability-Dose adjustment rate and withdrawal rate of chemotherapy drugs [Time frame: After the end of the 6th cycle of chemotherapy (21 days as 1 cycle)]
• Exploratory endpoint - Differences in pCR rates between predefined subgroups and factors influencing pCR in the study population. [Time frame: through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

• Age: 18-70 years;
• Clinical T2-T4d, or T1c with axillary lymph node positivity;
• Histopathologically confirmed HER2-positive invasive breast cancer; Note: HER2 positivity was determined by immunohistochemical (IHC) staining of 3+ or, if IHC 2+, by HER2 gene amplification as demonstrated by fluorescence in situ hybridization (FISH) assay；
• Have clinically measurable lesions: Measurable lesions shown on ultrasound, mammography, or MR (optional) within 1 month before randomization;
• No chemotherapy contraindications detected by organ and bone marrow function tests within 1 month before chemotherapy:

• Neutrophil count absolute value ≧2.0×109/L;
• Hemoglobin ≧ 100g/L;
• Platelet count ≧100×109/L;
• Total bilirubin <1.5 ULN (upper limit of normal);
• Creatinine < 1.5×ULN
• AST/ALT < 1.5×ULN;
• Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 55%);
• Reproductive age women, negative serum pregnancy test within 14 days before randomization;
• ECOG score 0 or 1;
• Signature of informed consent.

Exclusion criteria

• Stage IV (metastatic) breast cancer;
• Bilateral breast cancer;
• Patients who have received chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for this disease;
• Patients with a second primary malignancy, except for adequately treated skin cancer;
• Major non-breast cancer-related surgical procedures within the past 4 weeks before enrollment, or patients have not fully recovered from such surgical procedures;
• Severe heart disease or conditions that do not allow participation in the study, including but not limited to the following:

• History of heart failure or systolic dysfunction (LVEF < 50%);
• High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-grade atrioventricular conduction blocks (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block);
• Angina pectoris requiring anti-anginal drug therapy;
• Clinically significant valvular heart disease;
• ECG showing a transmural myocardial infarction;
• Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg);
• Due to severe and uncontrolled other medical conditions, the investigator considers chemotherapy to be contraindicated;
• Known history of allergy to any component of the study drugs; patients with a history of immune deficiency diseases, including HIV positivity, or patients with other acquired or congenital immune deficiency diseases, or a history of organ transplantation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Henan cancer hospital — Zhengzhou

Publications

• Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2 PMID 39612919

Identifiers

NCT: NCT04547907 · HELEN-006

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗